Darinaparsin

N/A

Report date: 2023/05/05 17:08:49
NME

Base Information

Drug NameDarinaparsin
Drug Alias Name达雷那新darinaparsinedarinaparsina达利那胂darinaparsinum +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis stimulantsReactive oxygen species stimulantsCell division inhibitors
TargetsReactive oxygen species
Therapy Area/IndicationsSolid tumoursLymphoproliferative DisordersMyeloproliferative Disorders +[12] 
Global Approved IndicationsLymphoma, T-Cell, Peripheral
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2022/06/20
Country/TerritoryCanadaUnited StatesTaiwan +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaIND
Originator CompaniesZiopharm Oncology IncMeiji Seika PharmaSolasia Pharma
China Registration ClassN/A

Develop Information

Active CompaniesSolasia PharmaNextpharma Technologies IncSolasia Pharma Kk +[6] 
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterAlaunos Therapeutics Inc
Active IndicationsCarcinoma, HepatocellularLymphoma, T-Cell, Peripheral
Inactive IndicationsSolid tumoursLymphoproliferative DisordersMyeloproliferative Disorders +[10] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG